Related Experiment Video
Updated: May 8, 2026
12:42
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Novel Kv1.3 blockers for immunosuppression: WO2012155199
1The Scripps Research Institute, Department of Molecular Therapeutics , 130 Scripps Way, Jupiter, FL , USA +1 561 228 2210 ; +1 561 228 3092 ; wnguyen@scripps.edu.
Expert Opinion on Therapeutic Patents
|August 24, 2013
Summary
New compounds block the voltage-gated Kv1.3 ion channel, offering a promising therapeutic target for autoimmune diseases like multiple sclerosis and rheumatoid arthritis.
Area of Science:
- Immunology
- Neuroscience
- Pharmacology
Background:
- Autoimmune disorders, including multiple sclerosis, psoriasis, diabetes, and rheumatoid arthritis, represent significant unmet medical needs.
- The voltage-gated Kv1.3 ion channel is implicated in the pathogenesis of various autoimmune diseases.
- Targeting ion channels presents a viable strategy for developing novel immunomodulatory therapies.
Purpose of the Study:
- To review and analyze a recent patent application detailing novel Kv1.3 channel blockers.
- To explore the chemical structure and biological activity of these newly discovered compounds.
- To compare these findings with existing knowledge and previous discoveries in the field of Kv1.3 channel modulation.
Main Methods:
- Review of a patent application from Bionomics/Merck Serono.
- Analysis of novel chemical structures described as Kv1.3 channel blockers.
- Evaluation of reported biological data, including IC50 values.
Main Results:
- Identification of a new chemotype of Kv1.3 blockers characterized by an amide core.
- Demonstration of potent inhibitory activity, with IC50 values potentially in the nanomolar range.
- These compounds exhibit promise for modulating immune cell function relevant to autoimmune conditions.
Conclusions:
- The patented compounds represent a significant advancement in the development of Kv1.3 channel inhibitors.
- This new class of blockers holds therapeutic potential for treating a range of autoimmune diseases.
- Further research and development are warranted to translate these findings into clinical applications.
More Related Videos
Related Concept Videos
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...